India Approves Its First Dengue Vaccine — QDENGA (Takeda): Eligibility, Doses & What It Means
On 20 July 2026, India approved its first-ever dengue vaccine, a landmark in the country's fight against one of its fastest-growing vector-borne diseases. The Drug Controller General of India (DCGI) granted market authorisation to QDENGA, Takeda's two-dose vaccine, for individuals aged 4 to 60 years. It protects against all four dengue serotypes, needs no prior infection and no pre-vaccination testing, and is expected to launch in the first half of 2027.
India's First Dengue Vaccine: The Announcement
India has approved its first dengue vaccine, marking a significant milestone in the country's fight against one of its fastest-growing vector-borne diseases. The Drug Controller General of India (DCGI) granted market authorisation under Form CT-20 of the New Drugs and Clinical Trials Rules, 2019, to QDENGA, Takeda's dengue vaccine, for individuals aged 4 to 60 years.
The vaccine requires two doses, given three months apart, and is designed to protect against all four dengue virus serotypes. Unlike an earlier dengue vaccine available internationally, QDENGA can be administered regardless of previous dengue infection and does not require pre-vaccination screening.
According to Dr Mahender Nayak, head of Intercontinental Markets at Takeda, the vaccine is expected to be launched in the first half of 2027. The company is working closely with the regulator and other stakeholders ahead of the launch. The pricing has not yet been finalised.
Who Can Take the Vaccine?
| Parameter | Details |
|---|---|
| Eligible age | 4 – 60 years |
| Doses | 2 |
| Gap between doses | 3 months |
| Previous dengue infection needed? | No |
| Pre-vaccination testing | Not required |
| Protects against | All 4 dengue serotypes |
Source: CDSCO approval.
How QDENGA Works
QDENGA (also known as TAK-003) is a live-attenuated, tetravalent dengue vaccine. It uses a weakened Dengue Serotype-2 virus as its genetic backbone, with components from the other three serotypes engineered into it to generate broad immune protection against all four serotypes.
- Administration: two 0.5 ml doses given subcutaneously, three months apart.
- No screening barrier: unlike the earlier internationally available vaccine, it does not require testing for prior dengue exposure before administration — a major practical advantage for mass immunisation.
- Evidence base: the DCGI approval rests on Takeda's global development programme of more than 28,000 participants across 19 Phase I, II and III trials. The India approval was specifically supported by a Phase III clinical trial in Indian participants aged 4 to 60, which found the vaccine safe, well tolerated and immunogenic.
- Efficacy & durability: in late-stage trials, QDENGA showed efficacy of a little over 80% against confirmed dengue one year after the second dose, and Takeda's seven-year follow-up data indicate continued protection against dengue infection and hospitalisation across all four serotypes.
QDENGA has received WHO prequalification and is recommended by the World Health Organization for use in dengue-endemic settings without pre-vaccination screening. Since its first approval (Indonesia, 2022), it has been approved in 43 countries, with more than 32 million doses distributed globally through public and private immunisation programmes. Countries such as Brazil have incorporated it into their national immunisation programme.
Why It Matters: India's Dengue Burden
The approval comes at a time when dengue continues to pose a major public health challenge. Spread by Aedes mosquitoes, dengue has no specific antiviral treatment and can rapidly progress to severe disease, requiring hospitalisation.
- According to Takeda, reported dengue cases in India have increased 11-fold over the past two decades.
- A landmark modelling study published in Nature estimated that India accounts for nearly 34% of the global dengue burden — the highest for any country.
- All four dengue serotypes circulate in India, contributing to recurrent outbreaks — which is why a vaccine protecting against all four matters so much.
- Official data recorded about 1.13–1.22 lakh dengue cases and 131 deaths in 2025, though experts believe the true number is far higher because many cases go unreported.
Dengue in India — Cases and Deaths (2021 to 2026)
| Year | Reported Cases (lakh) | Deaths |
|---|---|---|
| 2021 | 1.93 | 346 |
| 2022 | 2.33 | 303 |
| 2023 | 2.89 | 485 |
| 2024 | 2.34 | 297 |
| 2025 | 1.22 | 131 |
| 2026* | 0.069 (6.9k) | 10 |
*Provisional till 28 February 2026. Source: National Centre for Vector Borne Diseases Control (NCVBDC), Ministry of Health & Family Welfare.
For a country carrying a third of the world's dengue burden, a vaccine that works against all four serotypes without a screening barrier is not just a medical advance — it is a public-health turning point.
— Legacy IAS Faculty
QDENGA vs the Earlier Dengue Vaccine
The world's first licensed dengue vaccine, Dengvaxia (Sanofi), faced a major limitation: it was recommended only for people with a documented prior dengue infection, because vaccinating dengue-naïve individuals could raise the risk of severe disease on later infection. This required pre-vaccination screening, making mass roll-out difficult.
- QDENGA's advantage: it can be given regardless of prior infection and without screening — a decisive practical edge for a country with India's scale and dengue burden.
Prelims: QDENGA/TAK-003, Takeda, DCGI (Form CT-20, New Drugs & Clinical Trials Rules 2019), CDSCO, live-attenuated tetravalent vaccine, all four serotypes, 4–60 years, WHO prequalification, NCVBDC, Aedes mosquito — all are ready factual hooks.
Mains (GS2 Health / GS3 Sci & Tech): vaccine regulation and approval architecture in India, the National Vector Borne Disease Control Programme, the economics of vaccine pricing and access, "One Health," and climate change expanding the range of vector-borne diseases.
Frequently Asked Questions (FAQs)
What is India's first dengue vaccine?
Who can take the QDENGA vaccine and how many doses are needed?
Does QDENGA protect against all types of dengue?
When will the dengue vaccine be available in India and what is the price?
How is QDENGA different from the earlier dengue vaccine?
How big is India's dengue burden?
Key Takeaways
- Landmark approval: on 20 July 2026, the DCGI granted market authorisation (Form CT-20) to QDENGA (Takeda) — India's first dengue vaccine.
- Who & how: approved for ages 4–60; two doses, three months apart; no prior infection and no pre-vaccination testing required.
- The science: a live-attenuated tetravalent vaccine on a Dengue-2 backbone, protecting against all four serotypes; ~80% efficacy a year after dose two, with seven-year protection data.
- Global standing: WHO-prequalified, approved in 43 countries, with 32 million+ doses distributed; adopted by Brazil's national programme.
- Why it matters: India carries nearly 34% of the global dengue burden (Nature study), with ~1.22 lakh cases and 131 deaths in 2025 and all four serotypes circulating.
- Next steps: expected launch in the first half of 2027; pricing yet to be finalised.
